Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sm-TSP-2/Alhydrogel +/- AP 10-701 for Intestinal Schistosomiasis
NCT03110757Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sm-TSP-2 in schistosomiasis (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: The occurrence of new-onset chronic medical conditions (including AESI), The occurrence of solicited injection site reactogenicity and 3 more. Started May 2018; status: completed.
02
Drugs
Sm-TSP-2
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT03110757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110757.